Current Edition


Zealand becomes a lesson in the rigors of commercialization as a slow launch triggers 90% staff cut, CEO exit

It wasn’t supposed to be this way. Zealand Pharma should be in the honeymoon glow of its first drug launch with a drug approved less …

Continue Reading →

In major shake-up, Novartis combines pharma, oncology units, leaving cancer commercial head, CMO out of job

Novartis CEO Vas Narasimhan is giving the Swiss pharma a huge makeover even ahead of a possible spinoff of generics unit Sandoz, pushing out three …

Continue Reading →
cancer drugs

Merck, Roche and J&J among pharma players weighing Russian operations amid humanitarian tightrope walk

You can’t buy a Coke, Frappuccino or Big Mac in Russia anymore, but cancer patients may still be able to get Merck’s megablockbuster Keytruda. While …

Continue Reading →

On a roll, Sanofi raises Dupixent’s peak sales target to €13B-plus

Over the years, as Sanofi and Regeneron’s Dupixent racked up new indications and approached the French pharma giant’s 10 billion euro peak sales goal, analysts had started …

Continue Reading →

Take Part in the Pharmapack Survey

Pharmapack Europe is inviting its community to take part in an in-depth market insights survey exploring the drug delivery and pharma packaging industry and future …

Continue Reading →

US faces ‘critical moment’ in pricing reform that ‘won’t come again,’ nonprofit founder says after tallying 554 new hikes

With 2021 over, the pharmaceutical industry kicked off the New Year with one of its favorite pastimes: raising the prices on hundreds of branded meds. …

Continue Reading →

Antares Pharma develops novel auto-injector devices for innovative combination products

With over 30 years of experience in drug device engineering, Antares Pharma has nurtured its R&D prowess and specialized in creating custom designed drug delivery …

Continue Reading →

JPM 2022: Vertex’s Trikafta holds the line as company lays groundwork for gene editing launch

Vertex Pharmaceuticals is well known for its slew of cystic fibrosis medications, and newcomer Trikafta is pulling its weight. Over the course of 2021, the …

Continue Reading →

Totus tots up $40M in series A funding to go after competitive cancer space

Totus Medicines is making a play for the PI3Kα inhibitor market. Exiting stealth with a $40 million series A round, the Massachusetts-based biotech plans to …

Continue Reading →

The Future of Healthcare Ecosystems: The Real-World Impact of IDMP

A lot of lip service has been paid by the IDMP software industry to the potential of data-driven processes beyond regulatory compliance. But the opportunities …

Continue Reading →